Found 1 Presentation For Request "1335P"
1335P - Anti-tumour efficacy of cetuximab plus avelumab in NSCLC through induction of ADCC: Final data from CAVE-lung trial
- Morena Fasano (Napoli, Italy)
Abstract
Background
Antibody-Dependent Cell-mediated Cytotoxicity (ADCC) is a mechanism of immune antitumor activity of IgG1 monoclonal antibodies (mAbs), suggesting as novel therapy in non-small cell lung cancer (NSCLC) combination of anti-Epidermal Growth Factor Receptor (EGFR) Cetuximab (C) and anti-Programmed Death Ligand 1 Avelumab (A).
Methods
We validated LDH release assay to study induction of ADCC by C and A in 13 human lung cancer cell lines, using as effectors natural killers (NK) from healthy donors (HD) or patients (pts). We explored efficacy and safety of C plus A in a single arm proof of concept study in relapsed NSCLC. Potential predictive biomarkers were studied: induction of ADCC by LDH release assay using pts' NK, quantification of total circulating plasma cell-free DNA (cfDNA) levels, genomic profiling.
Results
Treatment with C plus A induced ADCC
Conclusions
Induction of ADCC assessed by LDH assay, reduction of cfDNA levels and early skin toxicity may predict clinical benefit to C plus A in NSCLC. Moreover, DDR alterations could be correlated with responsiveness to this combination, by affecting interplay between innate and adaptive immunity.
Clinical trial identification
EUDRACT 2017-004195-58.
Legal entity responsible for the study
The authors.
Funding
Merck Serono.
Disclosure
M. Fasano: Spouse/Financial dependant: Merck. A. Morabito: Advisory/Consultancy: Roche, AZ, Boehringer Ingelheim, Pfizer, Takeda, BMS, MSD. E. Maiello: Advisory/Consultancy: Lilly, Sanofi, Celgene, Servier. F. Ciardiello: Advisory/Consultancy: Roche, Amgen, Merck, Pfizer, Sanofi, Bayer, Servier, BMS, Celgene, Lilly; Research grant/Funding (institution): Bayer, Roche, Merck, Amgen, AZ, Ipsen . F. Morgillo: Advisory/Consultancy: MSD, Lilly; Research grant/Funding (institution): AZ. All other authors have declared no conflicts of interest.